Equities

AngioDynamics Inc

AngioDynamics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)7.14
  • Today's Change-0.300 / -4.03%
  • Shares traded418.78k
  • 1 Year change+14.98%
  • Beta0.6957
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for AngioDynamics, Inc. have a median target of 13.00, with a high estimate of 14.00 and a low estimate of 12.00. The median estimate represents a 82.07% increase from the last price of 7.14.
High96.1%14.00
Med82.1%13.00
Low68.1%12.00

Earnings history & estimates in USD

On Oct 03, 2024, AngioDynamics, Inc. reported 1st quarter 2025 losses of -0.11 per share. This result exceeded the -0.150 consensus loss of the 3 analysts covering the company and exceeded last year's 1st quarter results by 8.33%.
The next earnings announcement is expected on Jan 03, 2025.
Average growth rate-45.63%
AngioDynamics, Inc. reported annual 2024 losses of -0.38 per share on Jul 16, 2024.
Average growth rate-225.93%
More ▼

Revenue history & estimates in USD

AngioDynamics, Inc. had 1st quarter 2025 revenues of 67.49m. This missed the 67.93m consensus estimate of the 3 analysts following the company. This was 14.22% below the prior year's 1st quarter results.
Average growth rate-3.73%
AngioDynamics, Inc. had revenues for the full year 2024 of 303.91m. This was 10.28% below the prior year's results.
Average growth rate+3.92%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.